The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Open accessAbstract
BACKGROUND: Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, administered orally once daily) plus pembrolizumab (200 mg, administered intravenously every 3 weeks) or chemotherapy of the treating physician's choice (doxorubicin at 60 mg per square meter of body-surface area, administered intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). The two primary end points were progression-free survival as assessed on blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival. The end points were evaluated in patients with mismatch repair-proficient (pMMR) disease and in all patients. Safety was also assessed. RESULTS: A total of 827 patients (697 with pMMR disease and 130 with mismatch repair-deficient disease) were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients) or chemotherapy (416 patients). The median progression-free survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 6.6 vs. 3.8 months; hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.50 to 0.72; P<0.001; overall: 7.2 vs. 3.8 months; hazard ratio, 0.56; 95% CI, 0.47 to 0.66; P<0.001). The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0.001). Adverse events of grade 3 or higher occurred in 88.9% of the patients who received lenvatinib plus pembrolizumab and in 72.7% of those who received chemotherapy. CONCLUSIONS: Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer. (Funded by Eisai and Merck Sharp and Dohme [a subsidiary of Merck]; Study 309-KEYNOTE-775 ClinicalTrials.gov number, NCT03517449.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationLandscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
International patterns and trends in endometrial cancer incidence, 1978-2013.
Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx214 · Cited by 760
Current recommendations and recent progress in endometrial cancer
Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 573
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
Self-citationOtt, P. A., Bang, Y.-J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 506
Zhang, S., Gong, T.-T., Liu, F.-H., Jiang, Y.-T., Sun, H., Ma, X.-X., Zhao, Y.-H., & Wu, Q.-J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01440 · Cited by 229
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Soumerai, T. E., Donoghue, M. T. A., Bandlamudi, C., Srinivasan, P., Chang, M. T., Zamarin, D., Cadoo, K. A., Grisham, R. N., O'Cearbhaill, R. E., Tew, W. P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0412 · Cited by 146
Self-citationChemotherapy for advanced, recurrent or metastatic endometrial carcinoma
Vale, C. L., Tierney, J. F., Bull, S. J., & Symonds, P. R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003915.pub4 · Cited by 131
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
Oza, A. M., Pignata, S., Poveda, A. M., McCormack, M. M., Clamp, A. R., Schwartz, B., Cheng, J. D., Li, X. N., Campbell, K., Dodion, P. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8871 · Cited by 116
Self-citationKonecny, G. E., Finkler, N. J., García, A. A., Lorusso, D., Lee, P. S., Rocconi, R. P., Fong, P. C. C., Squires, M. S., Mishra, K., Upalawanna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70159-2 · Cited by 91
Self-citationMcMeekin, S., Dizon, D. S., BARTER, J. F., Scambia, G., Manzyuk, L., Lisyanskaya, A. S., Oaknin, A., Ringuette, S., Mukhopadhyay, P., Rosenberg, J., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.026 · Cited by 79
Second-line lenvatinib in patients with recurrent endometrial cancer
Vergote, I. B., Powell, M. A., Teneriello, M. G., Miller, D. S., García, A. A., Mikheeva, O. N., Bidziński, M., Cebotaru, C. L., Dutcus, C. E., Ren, M., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.039 · Cited by 77
Self-citationEmons, G., Kurzeder, C., Schmalfeldt, B., Neuser, P., de Gregorio, N., Pfisterer, J., Park‐Simon, T., Mahner, S., Schroder, W., Lück, H., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.025 · Cited by 75
Heudel, P., Fabbro, M., Roemer-Bécuwe, C., Kaminsky, M., Arnaud, A., Joly, F., Roche-Forestier, S., Meunier, J., Foa, C., You, B., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.430 · Cited by 72
Self-citationHow, J., Patel, S., Fellman, B. M., Lu, K. H., Hwu, P., Ramondetta, L. M., Westin, S. N., Fleming, N. D., Soliman, P. T., & Jazaeri, A. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.034 · Cited by 59
Vergote, I. B., Teneriello, M. G., Powell, M. A., Miller, D. S., García, A. A., Mikheeva, O. N., Pintér, T., Bidziński, M., Cebotaru, C. L., Fan, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5520 · Cited by 53
Self-citationPautier, P., Vergote, I. B., Joly, F., Melichar, B., Kutarska, E., Hall, G. D., Lisyanskaya, A. S., Reed, N. S., Oaknin, A., Ostapenko, V., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000862 · Cited by 41
Prendergast, E. N., Holman, L. L., Liu, A. Y., Lai, T. S., Campos, M. P., Fahey, J. N., Wang, X., Abdelaal, N., Rao, J. Y., Elvin, J. A., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.06.016 · Cited by 40
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
Taylor, M. H., Dutcus, C. E., Schmidt, E. V., Bagulho, T., Li, D., Shumaker, R. C., & Rasco, D. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.04 · Cited by 33
Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study
O’Malley, D. M., Marabelle, A., Jesus‐Acosta, A. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz250.052 · Cited by 29
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302312 · Cited by 758
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
Self-citation
Metadata
- Authors
- Makker, V., Colombo, N., Casado Herráez, A., Santin, A. D., Colomba, E., Miller, D. S., Fujiwara, K., Pignata, S., Baron-Hay, S., Ray-Coquard, I., Shapira-Frommer, R., Ushijima, K., Sakata, J., Yonemori, K., Kim, Y. M., Guerra, E. M., Sanli, U. A., McCormack, M. M., Smith, A. D., Keefe, S., Bird, S., Dutta, L., Orlowski, R. J., & Lorusso, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-02-03
- Volume
- 386
- Issue
- 5
- Pages
- 437-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4205306227
- Cited by
- 930
- References
- 28
- FWCI
- 168.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.